Not much detail yet r.e. actual numbers/stats but I like the fairly clear dose-response relationship seen with regard to efficacy, especially with such low patient numbers. Anyone know whether or not the design was powered to assess efficacy, or was the response seen greater than expected????. Efficacy trials now.
Ann: Trofinetide successful in Phase 2 trial in Fragile X, page-20
-
- There are more pages in this discussion • 84 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 582 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 16.36pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable